China Isotope & Radiation Corp (CIRC) is committed to providing innovative solutions in the field of isotope and radiation applications. As a leading company in this sector, CIRC upholds a strong corporate philosophy centered on excellence, integrity, and dedication. With a focus on technological advancement, CIRC aims to contribute to the development of nuclear medicine, industrial applications, and environmental protection. By leveraging its expertise and cutting-edge research, CIRC ensures the highest quality products and services that meet the evolving needs of customers across various industries. Emphasizing a customer-centric approach, CIRC strives for sustainable growth and remains at the forefront of the isotope and radiation industry.

China Isotope & Radiation Corp is primarily present in the People's Republic of China.

China Isotope & Radiation Corp has achieved several significant milestones. Firstly, the company established itself as a leading provider of radiopharmaceuticals in China. They have successfully developed and commercialized a range of radiopharmaceutical products for both diagnostic and therapeutic purposes. Additionally, China Isotope & Radiation Corp expanded its market share through various collaborations and partnerships with domestic and international stakeholders. They have also made significant advancements in the research and development of new radiopharmaceutical products, contributing to advancements in medical imaging and cancer treatment. Overall, China Isotope & Radiation Corp has emerged as a key player in the field of radiopharmaceuticals with continuous achievements and contributions to the healthcare industry.

China Isotope & Radiation Corp, also known as CIRC, is a leading Chinese company in the field of isotope and radiation applications. Established in 1989, CIRC has grown to become a key player in the global market. The company specializes in producing and providing a wide range of radioisotopes for medical, industrial, and agricultural purposes. With state-of-the-art facilities and advanced technology, CIRC ensures the highest quality and safety standards in its products. As a pioneer in China's isotope industry, CIRC has contributed significantly to advancements in nuclear medicine, cancer treatment, and environmental protection. The company's dedication to innovation and reliable solutions has earned it a prestigious position in the global market.

The main competitors of China Isotope & Radiation Corp in the market include Xian Tianlong Science & Technology Co., Ltd., China Nuclear Energy Technology Corporation Ltd., and China National Nuclear Corporation. These companies operate in the same industry and provide similar products and services. However, China Isotope & Radiation Corp differentiates itself through its strong research and development capabilities, advanced technology, and extensive network of distribution channels. Its commitment to quality and innovation enables the company to maintain a competitive edge in the market.

China Isotope & Radiation Corp (CIRC) is primarily active in the fields of nuclear medicine, radiopharmaceuticals, and radioisotopes. As a leading provider in these industries, CIRC specializes in the research, development, production, and sale of a wide range of products and services. By leveraging advanced technologies and resources, CIRC offers support to medical institutions, research organizations, and nuclear power plants. CIRC's expertise in nuclear medicine and radiopharmaceuticals allows for vital contributions to diagnostic imaging, therapeutic treatments, and industrial applications. With a steadfast commitment to innovation and quality, CIRC continues to play an instrumental role in advancing these critical sectors domestically and internationally.

The business model of China Isotope & Radiation Corp (CIRC) revolves around the production and sale of medical isotopes, radiopharmaceuticals, and radiation devices. CIRC operates in the nuclear medicine industry, specializing in the research, development, manufacturing, and distribution of these essential products. Their focus lies in supplying diagnostic and therapeutic solutions for various medical applications, including cancer diagnosis and treatment. CIRC integrates production facilities and a comprehensive supply chain to ensure the availability of products and services to medical institutions. With a commitment to advancing healthcare and improving patient outcomes, CIRC serves as a leading player in the global nuclear medicine market.

Det China Isotope & Radiation P/E-forhold er 22,18.

China Isotope & Radiation KUV er 0,37.

AlleAktien Kvalitetsscore for China Isotope & Radiation er 4/10.

Den forventede China Isotope & Radiation omsætning er 7,66 mia. CNY.

Den forventede China Isotope & Radiation indtjening er 126,69 mio. CNY.

China Isotope & Radiation Corp (CIRC) is a leading company in the Chinese nuclear industry. CIRC's business model is based on the production and sale of isotopes, radiation sources, and other nuclear medicine products. CIRC has various divisions, including isotopes, radiation sources, radiopharmaceuticals, medical devices, and X-ray contrast agents. CIRC is currently the largest manufacturer of radioactive isotopes in China and offers a wide range of products used for both diagnostic and therapeutic purposes. CIRC specializes in the production of radioactive isotopes used in nuclear medicine and radiation therapy, including isotopes like cobalt-60, iodine-131, and strontium-90. These isotopes are used for imaging in cancer patients and for the treatment of cancer and other diseases. In addition to isotopes, CIRC offers radiation sources for industrial applications, such as material testing, food industry, and archaeology, as well as for medical use in radiation therapy. CIRC also manufactures radiopharmaceuticals, which are radioactive substances designed specifically for the diagnosis and treatment of diseases in nuclear medicine. Some examples of radiopharmaceuticals offered include technetium-99m and fluorodeoxyglucose (FDG). CIRC also provides medical devices, including gamma cameras, PET scanners, and CT scanners, which are used for diagnosing and treating diseases and are an essential part of modern medical care. In addition to medical products, CIRC also offers X-ray contrast agents, which are substances used in X-ray examinations to enhance the visibility of certain tissues and organs. CIRC offers a wide range of X-ray contrast agents, including those specifically developed for use in MRI. CIRC's business model is centered around manufacturing and selling high-quality nuclear medicine products. The company has extensive experience and expertise in the nuclear industry and is committed to advancing the development of advanced products and services. CIRC aims to build and maintain long-term partnerships with its customers to ensure they always receive the best possible care.

China Isotope & Radiation udbetaler et udbytte på 0,44 CNY fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for China Isotope & Radiation, eller selskabet udbetaler ikke udbytte.

ISIN'en for China Isotope & Radiation er CNE1000031F4.

Tickeren for China Isotope & Radiation er 1763.HK.

I løbet af de sidste 12 måneder betalte China Isotope & Radiation en dividende på 0,48 CNY . Dette svarer til et dividendeudbytte på omkring 5,45 %. For de kommende 12 måneder vil China Isotope & Radiation sandsynligvis betale en dividende på 0,51 CNY.

Udbytteafkastet for China Isotope & Radiation er i øjeblikket 5,45 %.

China Isotope & Radiation betaler kvartalsvis udbytte. Dette uddeles i månederne august, juli, juli, oktober.

China Isotope & Radiation betalte udbytte hvert år i løbet af de sidste 8 år.

For de kommende 12 måneder forventes der dividender på 0,51 CNY. Dette svarer til et dividendeafkast på 5,78 %.

China Isotope & Radiation bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på China Isotope & Radiation fra den 22.11.2024 på 0,072 CNY, skulle du have haft aktien i din portefølje før ex-datoen den 27.9.2024.

Udbetalingen af det sidste udbytte blev foretaget den 22.11.2024.

I løbet af 2023 udbetalte China Isotope & Radiation 0,44 CNY i form af dividender.

Udbytterne fra China Isotope & Radiation udbetales i CNY.